Compare KKR & Co Inc (KKR) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Natera Inc. Common Stock — how do they compare? KKR & Co Inc trades at $86.13 (market cap $78.24B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: KKR & Co Inc is the larger of the two by market cap, and KKR & Co Inc pays a 0.89% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold KKR & Co Inc for 67 Days and Natera Inc. Common Stock for 0 Days on average.
| KKR | NTRA | |
|---|---|---|
Market Cap | $78.24B | $57.03B |
Volume | 9,217,096 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $142.75 | $425.64 |
52-Week Low | $83.88 | $179.42 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | $795.68M | $56.18B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR's stock is trading at $85.60, down 6.46% in the last session amid a bearish technical outlook. The company maintains strong profitability with a 14.97% net income margin and has beaten earnings estimates in two of the last three quarters. Recent business developments include multiple strategic investments and joint ventures, including a partnership with Thomson Reuters and new equipment finance platform Akrapoint Commercial Capital.
Despite near-term price weakness, KKR presents a compelling investment case with strong analyst support (88.9% buy ratings) and a consensus price target of $123.20 representing 44% upside. Key risks include volatile cash flow patterns and high leverage, but the company's diversified investment platform and active deal pipeline support long-term growth prospects.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
